ALLO
HEALTHCAREAllogene Therapeutics Inc
$2.31+0.14 (+6.45%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ALLO Today?
No stock-specific AI insight has been generated for ALLO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.86$4.46
$2.31
Fundamentals
Market Cap$797M
P/E Ratio—
EPS$-0.87
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume7.4M
Avg Volume (10D)—
Shares Outstanding345.0M
ALLO News
20 articles- Allogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateYahoo Finance·May 6, 2026
- William Blair Initiates Natera (NTRA) With OutperformYahoo Finance·May 2, 2026
- Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common StockYahoo Finance·May 1, 2026
- Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest InYahoo Finance·Apr 25, 2026
- H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO)Yahoo Finance·Apr 23, 2026
- Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and AustraliaYahoo Finance·Apr 21, 2026
- Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026Yahoo Finance·Apr 20, 2026
- Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common StockYahoo Finance·Apr 16, 2026
- Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed?Yahoo Finance·Apr 15, 2026
- Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune DiseasesYahoo Finance·Apr 15, 2026
- Allogene Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire Inc.·Apr 15, 2026
- ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 StudyYahoo Finance·Apr 14, 2026
- Company News for Apr 14, 2026Yahoo Finance·Apr 14, 2026
- Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T PlatformYahoo Finance·Apr 13, 2026
- Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common StockYahoo Finance·Apr 13, 2026
- Allogene Therapeutics Touts Early ALPHA3 Win: cema-cel MRD Clearance 58% vs 17%, No CRS/ICANSMarketbeat·Apr 13, 2026
- Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell LymphomaYahoo Finance·Apr 13, 2026
- Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCLYahoo Finance·Apr 13, 2026
- Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)?Yahoo Finance·Apr 12, 2026
- Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026Yahoo Finance·Apr 10, 2026
All 20 articles loaded
Price Data
Open$2.24
Previous Close$2.17
Day High$2.35
Day Low$2.22
52 Week High$4.46
52 Week Low$0.86
52-Week Range
$0.86$4.46
$2.31
Fundamentals
Market Cap$797M
P/E Ratio—
EPS$-0.87
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume7.4M
Avg Volume (10D)—
Shares Outstanding345.0M
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—